New research in mice suggests that memory deficits caused by a 22q11.2 microdeletion, which is the single largest genetic risk factor for schizophrenia, can be treated with antagonists of the glycogen synthase kinase 3 β (Gsk3β) protein (Tamura M et al. Neuron. doi:10.1016/j.neuron.2016.01.025 [published online February 18, 2016]). Gsk3β is involved in energy metabolism, neuronal cell development, and body pattern formation.
Hampton T. Compound Reverses Memory Deficits in Model of Schizophrenia. JAMA. 2016;315(13):1327. doi:10.1001/jama.2016.2507